Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up

Alessandro Antonelli¹, Silvia Martina Ferrari¹, Giusy Elia¹, Armando Patrizio¹, Poupak Fallahi²

Affiliations

¹ Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
² Department of Translational Research of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

PMID: 31328110
PMCID: PMC6606473
DOI: 10.21037/gs.2019.05.05

Editorial

Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up

Alessandro Antonelli et al. Gland Surg. 2019 Jun.

. 2019 Jun;8(3):298-300.

doi: 10.21037/gs.2019.05.05.

Authors

Alessandro Antonelli¹, Silvia Martina Ferrari¹, Giusy Elia¹, Armando Patrizio¹, Poupak Fallahi²

Affiliations

¹ Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
² Department of Translational Research of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

PMID: 31328110
PMCID: PMC6606473
DOI: 10.21037/gs.2019.05.05

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C, Descotes F, Decaussin-Petrucci M, Berthiller J, de la Fouchardière C, Giraudet AL, Bertholon-Gregoire M, Robinson P, Lifante JC, Lopez J, Borson-Chazot F. Bournaud C, et al. Eur J Cancer. 2019 Feb;108:41-49. doi: 10.1016/j.ejca.2018.12.003. Epub 2019 Jan 12. Eur J Cancer. 2019. PMID: 30648628

Cited by

Molecular features of aggressive thyroid cancer.
Elia G, Patrizio A, Ragusa F, Paparo SR, Mazzi V, Balestri E, Botrini C, Rugani L, Benvenga S, Materazzi G, Spinelli C, Antonelli A, Fallahi P, Ferrari SM. Elia G, et al. Front Oncol. 2022 Dec 20;12:1099280. doi: 10.3389/fonc.2022.1099280. eCollection 2022. Front Oncol. 2022. PMID: 36605433 Free PMC article. Review.
Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.
Bueno F, Abelleira E, von Stecher F, de Lima AP, Pitoia F. Bueno F, et al. Arch Endocrinol Metab. 2021 Nov 1;65(2):242-247. doi: 10.20945/2359-3997000000325. Epub 2021 Feb 15. Arch Endocrinol Metab. 2021. PMID: 33587835 Free PMC article.
Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer.
Hartl DM, Guerlain J, Breuskin I, Hadoux J, Baudin E, Al Ghuzlan A, Terroir-Cassou-Mounat M, Lamartina L, Leboulleux S. Hartl DM, et al. Cancers (Basel). 2020 Nov 6;12(11):3282. doi: 10.3390/cancers12113282. Cancers (Basel). 2020. PMID: 33171949 Free PMC article. Review.
Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience.
Bueno F, Smulever A, Califano I, Guerra J, Del Grecco A, Carrera JM, Giglio R, Rizzo M, Lingua A, Voogd A, Negueruela MDC, Abelleira E, Pitoia F. Bueno F, et al. Endocrine. 2023 Apr;80(1):134-141. doi: 10.1007/s12020-022-03295-2. Epub 2023 Jan 9. Endocrine. 2023. PMID: 36617605 Free PMC article.
Novel treatments for anaplastic thyroid carcinoma.
Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. Ferrari SM, et al. Gland Surg. 2020 Jan;9(Suppl 1):S28-S42. doi: 10.21037/gs.2019.10.18. Gland Surg. 2020. PMID: 32055496 Free PMC article. Review.

References

1. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-13. 10.1016/0092-8674(85)90170-9 - DOI - PubMed
1. Szostak JW, Blackburn EH. Cloning yeast telomeres on linear plasmid vectors. Cell 1982;29:245-55. 10.1016/0092-8674(82)90109-X - DOI - PubMed
1. Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 2013;38:426-34. 10.1016/j.tibs.2013.07.001 - DOI - PubMed
1. Xing M. Genetic-guided Risk Assessment and Management of Thyroid Cancer. Endocrinol Metab Clin North Am 2019;48:109-24. 10.1016/j.ecl.2018.11.007 - DOI - PMC - PubMed
1. Jin A, Xu J, Wang Y. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer. Medicine (Baltimore) 2018;97:e11548. 10.1097/MD.0000000000011548 - DOI - PMC - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up

Affiliations

Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources